A detailed history of Bailard, Inc. transactions in Dexcom Inc stock. As of the latest transaction made, Bailard, Inc. holds 41,495 shares of DXCM stock, worth $3.32 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
41,495
Previous 57,044 27.26%
Holding current value
$3.32 Million
Previous $6.47 Million 57.01%
% of portfolio
0.07%
Previous 0.18%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$64.0 - $116.06 $995,136 - $1.8 Million
-15,549 Reduced 27.26%
41,495 $2.78 Million
Q2 2024

Jul 25, 2024

SELL
$110.31 - $140.45 $549,343 - $699,441
-4,980 Reduced 8.03%
57,044 $6.47 Million
Q1 2024

May 08, 2024

BUY
$114.22 - $140.1 $725,982 - $890,475
6,356 Added 11.42%
62,024 $8.6 Million
Q4 2023

Feb 02, 2024

SELL
$75.49 - $124.16 $743,576 - $1.22 Million
-9,850 Reduced 15.03%
55,668 $6.91 Million
Q3 2023

Oct 24, 2023

BUY
$86.06 - $137.93 $1.29 Million - $2.06 Million
14,950 Added 29.56%
65,518 $6.11 Million
Q2 2023

Jul 20, 2023

BUY
$112.47 - $130.98 $1.01 Million - $1.17 Million
8,937 Added 21.47%
50,568 $6.5 Million
Q1 2023

May 08, 2023

BUY
$104.0 - $122.92 $626,392 - $740,347
6,023 Added 16.91%
41,631 $4.84 Million
Q4 2022

Feb 02, 2023

SELL
$84.98 - $122.67 $7,478 - $10,794
-88 Reduced 0.25%
35,608 $4.03 Million
Q3 2022

Oct 18, 2022

SELL
$76.35 - $94.18 $81,236 - $100,207
-1,064 Reduced 2.89%
35,696 $2.88 Million
Q2 2022

Jul 27, 2022

BUY
$67.99 - $132.89 $1.86 Million - $3.64 Million
27,386 Added 292.15%
36,760 $2.74 Million
Q1 2022

Apr 25, 2022

SELL
$94.08 - $130.2 $282 - $390
-3 Reduced 0.03%
9,374 $4.8 Million
Q4 2021

Feb 10, 2022

BUY
$129.87 - $162.82 $7,142 - $8,955
55 Added 0.59%
9,377 $5.04 Million
Q1 2021

May 13, 2021

BUY
$84.79 - $104.74 $790,412 - $976,386
9,322 New
9,322 $3.35 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $30.9B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Bailard, Inc. Portfolio

Follow Bailard, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.